Streetbeat News

Stock Prices

OSA

Roth MKM has maintained its Buy rating for ProSomnus (NASDAQ:OSA) but lowered its price target from $6.00 to $4.00. ProSomnus's shares are currently trading down 4.08% at $0.94 per share. A move to $4.00 would represent a 325.53% increase from the current share price.

Portfolio Pulse from Benzinga Insights

September 26, 2023 | 5:00 pm

CBAY

UBS has maintained its Buy rating for CymaBay Therapeutics (NASDAQ:CBAY) and increased its price target from $18.00 to $25.00. This new target price represents a 62.76% increase from the current share price. CymaBay Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for patients with liver and other chronic diseases.

Portfolio Pulse from Benzinga Insights

September 26, 2023 | 5:00 pm

USB

Over the past 3 months, 14 analysts have published their opinion on U.S. Bancorp (NYSE:USB) stock. The average price target for U.S. Bancorp is $45.0, with a high of $67.00 and a low of $37.00. This average price target has increased by 2.06% over the past month.

Portfolio Pulse from Benzinga Insights

September 26, 2023 | 5:00 pm

FOXF

In the last quarter, Fox Factory Hldg (NASDAQ:FOXF) received 4 bullish ratings from analysts. The company's average 12-month price target is $128.75, a decrease of 0.96% from the previous average price target of $130.00.

Portfolio Pulse from Benzinga Insights

September 26, 2023 | 5:00 pm

GD

Berenberg has maintained its Market Perform rating for General Dynamics (NYSE:GD) and raised its price target from $254.00 to $258.00. The new price target represents a 17.81% increase from the current share price. General Dynamics is a defense contractor and business jet manufacturer with segments in aerospace, marine, combat systems, and technologies.

Portfolio Pulse from Benzinga Insights

September 26, 2023 | 5:00 pm

APP

BTIG has maintained its Buy rating for AppLovin (NASDAQ:APP) and increased its price target from $40.00 to $46.00. AppLovin's shares are currently trading up 1.44% over the last 24 hours, at $38.75 per share. A move to $46.00 would account for a 18.71% increase from the current share price.

Portfolio Pulse from Benzinga Insights

September 26, 2023 | 5:00 pm

PACB

Pacific Biosciences (NASDAQ:PACB) has received mixed ratings from analysts in the last quarter, with one bullish rating and four indifferent ratings. The average 12-month price target for the company has increased by 13.6% from the previous average of $12.50 to $14.2, according to five analysts.

Portfolio Pulse from Benzinga Insights

September 26, 2023 | 5:00 pm

MAA

Mizuho has maintained its Neutral rating for Mid-America Apartment (NYSE:MAA) but lowered its price target from $159.00 to $133.00. MAA's shares are currently trading down 0.6% at $129.70 per share. A move to $133.00 would represent a 2.54% increase from the current share price.

Portfolio Pulse from Benzinga Insights

September 26, 2023 | 5:00 pm

DIS

Walt Disney Company (NYSE:DIS) shares are trading lower as investors await the outcome of a vote on the tentative agreement between production studios and the Writers Guild of America. The ongoing writers' strike has led to a complete shutdown in production of new content and significant profit losses for Disney. The company's shares have declined by more than 8% over the last three months and are down over 18% over the last year.

Portfolio Pulse from Erica Kollmann

September 26, 2023 | 4:59 pm

IONS

Ionis Pharmaceuticals Inc has released topline results for the Phase 3 Balance study of olezarsen in people with familial chylomicronemia syndrome (FCS). The trial met its primary efficacy endpoint with a significant reduction in triglyceride levels. The drug also showed a 100% reduction in acute pancreatitis events compared to placebo. Ionis plans to file a New Drug Application in early 2024 with the FDA. Following the news, IONS shares are up 7.83%.

Portfolio Pulse from Vandana Singh

September 26, 2023 | 4:57 pm